Get the Stockscreener App
282.80
1.90%
-5.49
Insulet Corporation stock is traded at $282.80, with a volume of 1.39M.
It is down -1.90% in the last 24 hours and up +2.43% over the past month.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.
See More
Previous Close:
$288.29
Open:
$276.35
24h Volume:
1.39M
Relative Volume:
2.58
Market Cap:
$19.84B
Revenue:
$1.98B
Net Income/Loss:
$420.90M
P/E Ratio:
48.42
EPS:
5.84
Net Cash Flow:
$218.20M
1W Performance:
+0.80%
1M Performance:
+2.43%
6M Performance:
+52.21%
1Y Performance:
+46.92%
1-Day Range:
$274.87
$286.66
1-Week Range:
$270.00
$288.95
52-Week Range:
$160.19
$289.46
Insulet Corporation Stock (PODD) Company Profile
Name
Insulet Corporation
Sector
Industry
Phone
978-600-7000
Address
100 NAGOG PARK, ACTON, MA
Compare PODD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
282.80 | 19.84B | 1.98B | 420.90M | 218.20M | 5.84 |
|
ABT
Abbott Laboratories
|
134.92 | 234.01B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
104.49 | 154.20B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
382.78 | 146.06B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
89.94 | 115.42B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.30 | 43.23B | 5.72B | 4.17B | 490.10M | 6.97 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-24 | Initiated | Bernstein | Outperform |
| May-30-24 | Initiated | Redburn Atlantic | Buy |
| May-07-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-21-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-04-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-02-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-21-23 | Upgrade | Citigroup | Neutral → Buy |
| Aug-21-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-11-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-19-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Jul-28-20 | Initiated | Wells Fargo | Overweight |
| Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-03-20 | Initiated | BofA/Merrill | Neutral |
| Mar-31-20 | Downgrade | Berenberg | Buy → Hold |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-10-19 | Initiated | CFRA | Sell |
| Oct-23-19 | Initiated | Stifel | Hold |
| Oct-18-19 | Downgrade | Canaccord Genuity | Buy → Hold |
| Oct-14-19 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-04-19 | Downgrade | UBS | Buy → Neutral |
| Oct-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-06-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-10-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-06-19 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-20-18 | Initiated | Berenberg | Buy |
| Feb-22-18 | Reiterated | Barclays | Overweight |
| Jan-08-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Nov-03-17 | Upgrade | Canaccord Genuity | Hold → Buy |
| Sep-15-17 | Initiated | Barclays | Overweight |
View All
Insulet Corporation Stock (PODD) Latest News
Insulet Stock: Aiding Patients And Investors (NASDAQ:PODD) - Seeking Alpha
Insulet’s Earnings Highlight Omnipod Success Amid Challenges - TipRanks
Insulet's Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst - Benzinga
Insulet stock price target raised to $293 by Stifel - Investing.com Canada
Stifel Nicolaus Adjusts Insulet Price Target to $293 From $245 -February 21, 2025 at 09:21 am EST - Marketscreener.com
Leerink Partners Adjusts Insulet Price Target to $314 From $278 -February 21, 2025 at 09:19 am EST - Marketscreener.com
Assessing Insulet: Insights From 6 Financial Analysts - Benzinga
PODD Stock Falls Despite Q4 Earnings and Revenue Beat, Margins Rise - Yahoo Finance Australia
Insulet Corporation (NASDAQ:PODD) Q4 2024 Earnings Call Transcript - Insider Monkey
Insulet stock target raised to $324 by Canaccord Genuity - Investing.com South Africa
Insulet Corporation (PODD) PT Raised to $293 at Stifel - StreetInsider.com
Insulet stock price target raised to $310 by BTIG - Investing.com South Africa
Insulet Corporation (PODD) PT Raised to $324 at Canaccord Genuity - StreetInsider.com
Insulet Updates Equity Agreements for Fiscal 2025 - TipRanks
INSULET CORP SEC 10-K Report - TradingView
Insulet Corporation (PODD) PT Raised to $310 at BTIG - StreetInsider.com
Blue Owl Capital, Insulet, Unity Software - TradingView
Insulet Corp (PODD) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic Expansion Amidst Challenges - GuruFocus.com
Insulet’s Revenue Surpasses $2 Billion with Strong Growth - TipRanks
Insulet Corp (PODD) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic Expansion ... - Yahoo Finance
Insulet Reports Full Year 2024 Revenue Increase of 22% and Fourth Quarter 2024 Revenue Increase of 17% Year-Over-Year - BioSpace
Insulet: Q4 Earnings Snapshot - Thehour.com
Earnings call transcript: Insulet beats Q4 2024 forecasts, stock dips By Investing.com - Investing.com Canada
Insulet earnings beat by $0.12, revenue topped estimates - Investing.com
Insulet Corp (PODD) Q4 Earnings: EPS of $1.39 Beats Estimate, Revenue Surpasses Expectations at $597.5 Million - GuruFocus.com
Compared to Estimates, Insulet (PODD) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
Insulet (PODD) Q4 Earnings and Revenues Top Estimates - Yahoo Finance
Insulet Corporation (NASDAQ:PODD) Reports Strong Q4 2024 PerformanceNews and Statistics - IndexBox, Inc.
Insulet beats quarterly profit estimates on insulin pump demand - Reuters
Insulet’s (NASDAQ:PODD) Q4: Beats On Revenue, Quarterly Revenue Guidance Slightly Exceeds Expectations - Yahoo Finance
Insulet: Q4 Earnings Snapshot -February 20, 2025 at 04:34 pm EST - Marketscreener.com
Insulet beats Q4 estimates, sees strong 2025 growth By Investing.com - Investing.com Australia
Insulet beats Q4 estimates, sees strong 2025 growth - Investing.com
Insulet Q4 Adjusted EPS Decreases, Revenue Rises -February 20, 2025 at 04:11 pm EST - Marketscreener.com
Agree To Purchase Insulet Corp At $200, Earn 36.5% Annualized Using Options - Nasdaq
Insulet Earnings: What To Look For From PODD - The Globe and Mail
Insulet Earnings: What To Look For From PODD By Stock Story - Investing.com Canada
(PODD) Trading Report - Stock Traders Daily
Insulet (NASDAQ:PODD) Is Experiencing Growth In Returns On Capital - Simply Wall St
Certuity LLC Invests $245,000 in Insulet Co. (NASDAQ:PODD) - MarketBeat
Summit Trail Advisors LLC Acquires Shares of 1,882 Insulet Co. (NASDAQ:PODD) - MarketBeat
Sumitomo Mitsui DS Asset Management Company Ltd Grows Position in Insulet Co. (NASDAQ:PODD) - MarketBeat
PODDInsulet to Assume Distribution and Commercial Support for Its Omnipod® System in Europe - br.ADVFN.com
Choreo LLC Decreases Stock Position in Insulet Co. (NASDAQ:PODD) - MarketBeat
Stay Ahead of the Game With Insulet (PODD) Q4 Earnings: Wall Street's Insights on Key Metrics - Yahoo Finance
Insulet Co. (NASDAQ:PODD) Stake Boosted by Sumitomo Mitsui Trust Group Inc. - MarketBeat
Insulet Co. (NASDAQ:PODD) Shares Sold by Stephens Investment Management Group LLC - MarketBeat
Insulet Corporation vs Menarini Diagnostics and EOFlow - Solicitors Journal
Tubeless Insulin Pumps Market to Grow with Leading Key Players - openPR
Insulet Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Yousif Capital Management LLC Acquires 1,554 Shares of Insulet Co. (NASDAQ:PODD) - MarketBeat
Insulet Corporation Stock (PODD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.16%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):